{{Rsnum
|rsid=9507577
|Gene=ATP8A2
|Chromosome=13
|position=25788938
|Orientation=plus
|GMAF=0.4642
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
|Gene_s=ATP8A2
}}{{ population diversity
| geno1=(G;G)
| geno2=(G;T)
| geno3=(T;T)
| CEU | 12.4 | 55.8 | 31.9
| HCB | 26.9 | 42.5 | 30.6
| JPT | 28.6 | 46.4 | 25.0
| YRI | 49.0 | 42.9 | 8.2
| ASW | 31.6 | 56.1 | 12.3
| CHB | 26.9 | 42.5 | 30.6
| CHD | 29.6 | 41.7 | 28.7
| GIH | 10.9 | 40.6 | 48.5
| LWK | 70.0 | 26.4 | 3.6
| MEX | 36.2 | 51.7 | 12.1
| MKK | 57.7 | 37.2 | 5.1
| TSI | 20.6 | 48.0 | 31.4
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs9507577
|Name_s=
|Gene_s=ATP8A2
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 89. Study population/ethnicity: 89 Yorubans. Significance metric(s): p = 0.00008. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109325
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs9507577
|overall_frequency_n=64
|overall_frequency_d=128
|overall_frequency=0.5
|n_genomes=36
|n_genomes_annotated=0
|n_haplomes=50
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Illumina Human 1M}}